Drug Trial Radar · NCT05377580
A Study to Evaluate IBI112 in the Treatment of Moderate to Severe Active Ulcerative Colitis
Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
150
Actual
Start
Jul 1, 2022
Primary completion
Jun 21, 2024
Study completion Aug 7, 2025
Sponsor
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.Industry
- Sponsor type
- Industry
- First posted
- May 17, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
To evaluate the efficacy of IBI112 induction therapy in patients with moderate and severe active Ulcerative Colitis (UC) to achieve clinical remission.
Conditions
- Ulcerative Colitis (UC)
Interventions
Period 1 IBI112 PlaceboDrug
Intravenous Injection
Period 2 IBI112 dose 3Drug
Subcutaneous injections
Period 1 IBI112 dose 1Drug
Intravenous Injection
Period 1 IBI112 dose 2Drug
Intravenous Injection
Period 2 IBI112 dose 4Drug
Intravenous Injection
Period 2 IBI112 PlaceboDrug
Subcutaneous injections
Primary outcomes
What the sponsor says the trial is designed to measure.
- Evaluate the effectiveness of IBI112 in inducing clinical remission in patients with moderately to severely active ulcerative colitis (UC)Time frame: week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
First Affiliated Hospital of Sun Yat-sen University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.